ListarMD - Artículos por tema "Mamas - Cáncer"
Mostrando ítems 1-6 de 6
-
A microRNA signature associated with early recurrence in breast cancer.
Pérez-Rivas, Luis G.; Jerez-Aragonés, José Manuel
; Carmona, Rosario; De Luque, Vanessa; Vicioso-Recio, Luis Prudencio; Claros-Díaz, Manuel Gonzalo; Viguera-Mínguez, Enrique; Pajares, Bella; Sánchez-Muñoz, Alfonso; Ribelles, Nuria; Alba-Conejo, Emilio; Lozano-Castro, José[et al.] (PLOS, 2014-03-14)
Recurrent breast cancer occurring after the initial treatment is associated with poor outcome. A bimodal relapse pattern after surgery for primary tumor has been described with peaks of early and late recurrence occurring ... -
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
Godoy-Ortiz, Ana; Sánchez-Muñoz, Alfonso; Chica Parrado, María del Rosario; Álvarez-Pérez, Martína; Ribelles, Nuria; Rueda-Domínguez, Antonio; Alba-Conejo, Emilio[et al.] (Frontiers Media, 2019)
The main obstacle for designing effective treatment approaches in breast cancer is the extensive and the characteristic heterogeneity of this tumor. The vast majority of critical genomic changes occurs during breast cancer ... -
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HRþ)/HER2-negative advanced breast cancer patients.
Ribelles, Nuria; Jerez-Aragonés, José Manuel; Rodríguez-Brazzarola, Pablo; Jiménez-Rodríguez, Begoña; Díaz-Redondo, Tamara; Mesa, Héctor; Márquez, Antonia; Sánchez-Muñoz, Alfonso; Pajares, Bella; Carabantes, Francisco; Bermejo-Pérez, María José; Villar, Ester; Domínguez-Recio, María Emilia; Saez-Lara, Enrique; Gálvez Carvajal, Laura; Godoy-Ortiz, Ana; Franco, Leónardo; Ruiz-Medina, Sofía; López, Irene; Alba-Conejo, Emilio[et al.] (Elsevier, 2021)
Background: CDK4/6 inhibitors plus endocrine therapies are the current standard of care in the first-line treatment of HRþ/HER2-negative metastatic breast cancer, but there are no well-established clinical or molecular ... -
Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes
Sánchez-Muñoz, Alfonso; Vicioso-Recio, Luis Prudencio; Santonja, Angela; Alvaréz, Martina; Plata-Fernández, Yéssica; Miramón, José; Zarcos, Irene; Ramírez-Tortosa, César; Montes-Torres, Julio; Jerez-Aragonés, José Manuel; De Luque, Vanessa; Llácer, Casilda; Fernández-De Sousa, C.E.; Pérez-Villa, Lidia; Alba-Conejo, Emilio[et al.] (Elsevier, 2018-02)
Male breast cancer is a rare disease that is still poorly understood. It is mainly classified by immunohistochemistry as a luminal disease. In this study, we assess for the first time the correlation between molecular ... -
Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
Sánchez-Muñoz, Alfonso; Vicioso-Recio, Luis Prudencio; Santonja, Ángela; Álvarez-Pérez, Martína; Plata-Fernández, Yéssica; Miramón, José; Zarcos, Irene; Ramírez-Tortosa, C.L.; Montes-Torres, Julio; Jérez, J.M.; De Luque, Vanessa; Llácer, Casilda; Fernández-De Sousa, C.E.; Pérez-Villa, Lidia; Alba-Conejo, Emilio[et al.] (Elsevier, 2017-09-22)
Male breast cancer is a rare disease that is still poorly understood. It is mainly classified by immunohistochemistry as a luminal disease. In this study, we assess for the first time the correlation between molecular ... -
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER1) node-negative breast cancer
Albanell, J.; González, A.; Ruiz-Borrego, M; Alba-Conejo, Emilio; García-Saenz, J.A.; Corominas, J. M.; Burgues, O.; Furio, V.; Rojo, A.; Palacios, J.; Bermejo, B.; Martínez-García, M.; Limón, L.M.; Sánchez-Muñoz, Alfonso; Martín, M.; Tusquets, I.; Rojo, R.; Colomer, R.; Faull, F.; Lluch, A.[et al.] (Elsevier, 2012-03)
This study examined the impact of the Recurrence Score (RS) in Spanish breast cancer patients and explored the associations between clinicopathological markers and likelihood of change in treatment recommendations. Patients ...